GlassScriptPhysician profile
Tiffany Park
NPI 1902458268
$1,481.29
in general payments reported to CMS, 2019-2025
26 companies · $57.07 in 2025
The $57.07 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $492 · 2023: $229 · 2024: $271 · 2025: $57.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $263.29 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $256.15 | 2021-2024 | |
| Novo Nordisk INC | $137.08 | 2021-2024 | Ozempic |
| Abbott Laboratories | $135.00 | 2021 | |
| Glaxosmithkline, LLC. | $78.44 | 2021-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $59.04 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $56.00 | 2021-2022 | |
| Sanofi Pasteur INC. | $54.99 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $50.00 | 2022-2023 | |
| Neurelis, INC. | $42.34 | 2021-2022 | |
| Inspire Medical Systems, INC. | $41.90 | 2024-2025 | Inspire |
| Relievant Medsystems, INC. | $30.46 | 2021 | |
| Idorsia Pharmaceuticals US INC | $28.83 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $27.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.52 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $23.47 | 2021 | |
| Tris Pharma INC | $22.08 | 2023 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2021 | |
| Dexcom, INC. | $21.57 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $19.67 | 2022 | |
| Hologic Sales and Service, LLC | $18.47 | 2023 | Aptima |
| Merck Sharp & Dohme LLC | $14.82 | 2024 | Vaxneuvance, Vaxelis, Capvaxive |
| Supernus Pharmaceuticals, INC. | $14.45 | 2021 | |
| Seqirus USA INC | $14.07 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.